Serelaxin when added to standard therapy in acute heart failure
Research type
Research Study
Full title
A multicenter, randomized, double-blind, placebo- controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients
IRAS ID
131150
Contact name
Iain Squire
Contact email
Sponsor organisation
Novartis Pharma Services AG
Eudract number
2013-001498-25
ISRCTN Number
n/a
Clinicaltrials.gov Identifier
n/a
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
13/EM/0251
Date of REC Opinion
15 Jul 2013
REC opinion
Further Information Favourable Opinion